Helix BioPharma Reports Financial Results Amid Financing Challenges and Pipeline Focus

Helix BioPharma Corp. reported financial results and filed interim financial statements for the three- and six-month periods ended January 31, 2026, revealing a net loss of $694,000 for the quarter and $1,702,000 for the six-month period. These figures represent a decrease from losses of $1,375,000 and $2,711,000 for the comparable periods in 2025, primarily attributed to the completion of the LDOS006 clinical trial in metastatic pancreatic adenocarcinoma and reduced research activities. The company's cash position declined sharply to $31,000 as of January 31, 2026, from $1,996,000 a year earlier, creating significant operational challenges.

Chief Executive Officer Thomas Mehrling acknowledged the difficult capital markets environment for small-cap biotech companies while emphasizing the company's focus on securing financing to advance into its next phase. Management and the board are actively pursuing financing opportunities aimed at securing approximately twelve months of operating runway, which would support near-term objectives including listing on a U.S. securities exchange. The company expressed cautious optimism about these efforts and expects to communicate further on its roadmap soon.

A significant financing setback occurred when Quantum Global Ventures AG, which had entered into a subscription agreement for $33,370,000 in December 2025, declared bankruptcy after the reporting period, resulting in the company receiving none of the anticipated proceeds. Following this development, Helix signed a term sheet with Alumni Capital Limited regarding a potential financing transaction, though specific commercial terms remain confidential. The company's financial statements indicate that existing cash reserves are insufficient to meet anticipated cash needs for working capital and capital expenditures through the next twelve months, nor sufficient to complete current research and development activities.

The company's pipeline includes clinical-stage antibody-enzyme conjugate L-DOS47, which has completed Phase Ib studies in non-small cell lung cancer, along with pre-IND candidates LEUMUNA and GEMCEDA. These developments occur against a backdrop where the company's financial position reflects broader challenges in biotechnology financing, particularly for companies advancing complex oncology treatments. The interim filings are available on the company's profile at https://www.sedarplus.ca and on its website at https://www.helixbiopharma.com/filings-and-financials/.

The financial results highlight the precarious position of development-stage biotechnology companies that must balance advancing promising therapies with maintaining adequate financial resources. With per-share losses of $0.01 for the quarter and $0.05 for the six-month period, compared to $0.03 and $0.02 respectively for the prior year periods, the company's ability to secure sustainable financing will be crucial for continuing its research into treatments for hard-to-treat cancers. The situation underscores the importance of reliable financing partners in the biotechnology sector, where clinical development timelines are lengthy and capital intensive.